Ira W. Deveson

Ira W. Deveson

Auto-generated profile, based on publicly available information

Ira W. Deveson

Garvan Institute of Medical Research, Darlinghurst, NSW, Australia

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2021 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
IDIra W. Deveson
Ira W. Deveson
BGBinsheng Gong
Binsheng Gong
KLKevin Lai
Kevin Lai
JLJennifer S. LoCoco
Jennifer S. LoCoco
TRTodd A. Richmond
Todd A. Richmond
JXJoshua Xu
Joshua Xu

9 December 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
RBRowena A. Bull
Rowena A. Bull
TAThiruni N. Adikari
Thiruni N. Adikari
JFJames M. Ferguson
James M. Ferguson
JHJillian M. Hammond
Jillian M. Hammond
ISIgor Stevanovski
Igor Stevanovski
IDIra W. Deveson
Ira W. Deveson
Viral whole-genome sequencing (WGS) provides critical insight into the transmission and evolution of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Long-read sequencing devices from Oxford Nanopore Technologies (ONT) promise significant improvements in turnaround time, portability and cost, compared to established short-read sequencing platforms for viral WGS (e.g., Illumina). However, adoption of ONT sequencing for SARS-CoV-2 surveillance has been limited due to common concerns around sequencing accuracy. To address this, here we perform viral WGS with ONT and Illumina platforms on 157 matched SARS-CoV-2-positive patient specimens and synthetic RNA controls, enabling rigorous evaluation of analytical performance. We report that, despite the elevated error rates observed in ONT sequencing reads, highly accurate consensus-level sequence determination was achieved, with single nucleotide variants (SNVs) detected at >99% sensitivity and >99% precision above a minimum ~60-fold coverage depth, thereby ensuring suitability for SARS-CoV-2 genome analysis. ONT sequencing also identified a surprising diversity of structural variation within SARS-CoV-2 specimens that were supported by evidence from short-read sequencing on matched samples. However, ONT sequencing failed to accurately detect short indels and variants at low read-count frequencies. This systematic evaluation of analytical performance for SARS-CoV-2 WGS will facilitate widespread adoption of ONT sequencing within local, national and international COVID-19 public health initiatives.

19 June 2017 in Nature Reviews Genetics
Verified
Journal Article
Closed access
SHSimon A. Hardwick
Simon A. Hardwick
IDIra W. Deveson
Ira W. Deveson
TMTim R. Mercer
Tim R. Mercer

4 March 2022 in Science Advances
Verified
Journal Article
Open access
ISIgor Stevanovski
Igor Stevanovski
SCSanjog R. Chintalaphani
Sanjog R. Chintalaphani
HGHasindu Gamaarachchi
Hasindu Gamaarachchi
JFJames M. Ferguson
James M. Ferguson
SPSandy Pineda
Sandy Pineda
IDIra W. Deveson
Ira W. Deveson
More than 50 neurological and neuromuscular diseases are caused by short tandem repeat (STR) expansions, with 37 different genes implicated to date. We describe the use of programmable targeted long-read sequencing with Oxford Nanopore’s ReadUntil function for parallel genotyping of all known neuropathogenic STRs in a single assay. Our approach enables accurate, haplotype-resolved assembly and DNA methylation profiling of STR sites, from a list of predetermined candidates. This correctly diagnoses all individuals in a small cohort ( n = 37) including patients with various neurogenetic diseases ( n = 25). Targeted long-read sequencing solves large and complex STR expansions that confound established molecular tests and short-read sequencing and identifies noncanonical STR motif conformations and internal sequence interruptions. We observe a diversity of STR alleles of known and unknown pathogenicity, suggesting that long-read sequencing will redefine the genetic landscape of repeat disorders. Last, we show how the inclusion of pharmacogenomic genes as secondary ReadUntil targets can further inform patient care.

27 March 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
EHErin E. Heyer
Erin E. Heyer
IDIra W. Deveson
Ira W. Deveson
DWDanson Wooi
Danson Wooi
CSChristina I. Selinger
Christina I. Selinger
RLRuth J. Lyons
Ruth J. Lyons
JBJames Blackburn
James Blackburn
Fusion genes are a major cause of cancer. Their rapid and accurate diagnosis can inform clinical action, but current molecular diagnostic assays are restricted in resolution and throughput. Here, we show that targeted RNA sequencing (RNAseq) can overcome these limitations. First, we establish that fusion gene detection with targeted RNAseq is both sensitive and quantitative by optimising laboratory and bioinformatic variables using spike-in standards and cell lines. Next, we analyse a clinical patient cohort and improve the overall fusion gene diagnostic rate from 63% with conventional approaches to 76% with targeted RNAseq while demonstrating high concordance for patient samples with previous diagnoses. Finally, we show that targeted RNAseq offers additional advantages by simultaneously measuring gene expression levels and profiling the immune-receptor repertoire. We anticipate that targeted RNAseq will improve clinical fusion gene detection, and its increasing use will provide a deeper understanding of fusion gene biology.

1 July 2017 in Trends in Genetics
Verified
Journal Article
Closed access
IDIra W. Deveson
Ira W. Deveson
SHSimon A. Hardwick
Simon A. Hardwick
TMTim R. Mercer
Tim R. Mercer
JMJohn Mattick
John Mattick